Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Animals
Anticonvulsants
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Carcinoma, Neuroendocrine
/ drug therapy
Cell Degranulation
/ drug effects
Cell Differentiation
Cell Proliferation
/ drug effects
Drug Repositioning
Gene Expression Regulation, Neoplastic
Humans
Levetiracetam
/ therapeutic use
Male
Mast Cells
/ immunology
Matrix Metalloproteinase 9
/ metabolism
Membrane Glycoproteins
/ metabolism
Mice, Inbred C57BL
Mice, Transgenic
Neoplasms, Experimental
Nerve Tissue Proteins
/ metabolism
Prostatic Neoplasms
/ drug therapy
Tumor Cells, Cultured
drug repurposing
mast cells
mouse models
neuroendocrine differentiation
prostate cancer
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
10
2020
accepted:
12
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
27
8
2021
Statut:
epublish
Résumé
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an
Identifiants
pubmed: 33737929
doi: 10.3389/fimmu.2021.622001
pmc: PMC7960782
doi:
Substances chimiques
Anticonvulsants
0
Antineoplastic Agents
0
Membrane Glycoproteins
0
Nerve Tissue Proteins
0
SV2A protein, human
148845-93-6
Levetiracetam
44YRR34555
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
622001Informations de copyright
Copyright © 2021 Sulsenti, Frossi, Bongiovanni, Cancila, Ostano, Fischetti, Enriquez, Guana, Chiorino, Tripodo, Pucillo, Colombo and Jachetti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Eur J Cancer Prev. 2012 Jan;21(1):55-64
pubmed: 21979296
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Cancer Immunol Res. 2018 May;6(5):552-565
pubmed: 29523597
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Front Physiol. 2018 May 15;9:500
pubmed: 29867548
J Exp Clin Cancer Res. 2019 Aug 22;38(1):368
pubmed: 31439015
Oncotarget. 2016 Jan 26;7(4):3905-20
pubmed: 26700622
Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
Cancer Res. 2011 Sep 15;71(18):5987-97
pubmed: 21896641
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Cancer Discov. 2017 Jul;7(7):736-749
pubmed: 28411207
J Pathol. 2018 Oct;246(2):244-253
pubmed: 30015382
Stem Cells Transl Med. 2013 Sep;2(9):678-89
pubmed: 23884639
Epilepsy Behav. 2007 Sep;11(2):247
pubmed: 17692573
CNS Drugs. 2011 Oct 1;25(10):901-5
pubmed: 21936590
Science. 2006 Apr 28;312(5773):592-6
pubmed: 16543415
Am J Pathol. 2000 Oct;157(4):1299-309
pubmed: 11021834
Mol Cancer Ther. 2017 Feb;16(2):365-375
pubmed: 27980106
Biol Pharm Bull. 2015;38(6):827-35
pubmed: 25787895
Adv Exp Med Biol. 2011;716:62-90
pubmed: 21713652
Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903
pubmed: 22869752
J Clin Pharm Ther. 2013 Feb;38(1):68-70
pubmed: 22725831
Neuro Oncol. 2010 Sep;12(9):917-27
pubmed: 20525765
Prostate. 2009 Aug 1;69(11):1143-50
pubmed: 19399787
Eur Urol. 2014 Mar;65(3):516-20
pubmed: 24246407
Allergy. 2019 Jan;74(1):53-63
pubmed: 30390314
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Mol Sci. 2020 Feb 06;21(3):
pubmed: 32041153
Neural Regen Res. 2020 Nov;15(11):1995-2007
pubmed: 32394947
J Pharmacol Exp Ther. 2005 May;313(2):720-30
pubmed: 15644427
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
pubmed: 7724580
Epilepsy Res. 2010 Jun;90(1-2):110-20
pubmed: 20435441
Am J Pathol. 2008 Jan;172(1):236-46
pubmed: 18156212
Front Oncol. 2014 Mar 25;4:60
pubmed: 24724054
Neoplasia. 2007 Nov;9(11):938-50
pubmed: 18030362
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Cell Calcium. 2001 Oct;30(4):285-96
pubmed: 11587552
Trends Immunol. 2018 Feb;39(2):151-162
pubmed: 29196147
Epilepsia. 2004 Jul;45(7):737-44
pubmed: 15230695
Clin Epigenetics. 2016 Sep 15;8:98
pubmed: 27651838
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
pubmed: 15210974
Intern Med. 2018 Mar 1;57(5):721-724
pubmed: 29151513
Semin Cancer Biol. 2021 Jan;68:279-290
pubmed: 32437876
J Clin Oncol. 2016 Mar 1;34(7):731-9
pubmed: 26786929
Neuropharmacology. 2020 May 15;168:107966
pubmed: 32120063